| Name | Title | Contact Details |
|---|
Providence is a clinical-stage biotechnology company pioneering mRNA therapeutics and vaccines with a focus on infectious diseases and oncology. Initially founded as a cancer vaccines company in 2015, in response to a worldwide need for a COVID-19 vaccine, Providence expanded its focus beyond oncology therapies to develop an mRNA vaccine for COVID-19. Providence works with multiple industry collaborators, universities, nongovernmental agencies and multiple arms of the Government of Canada to discover and develop vaccines and treatments for infectious diseases and cancer. This has resulted in the development of an mRNA vaccine platform that includes a proprietary design algorithm and proprietary, scalable manufacturing processes.
emcresearch is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Inflammatix, Inc. is a venture-backed startup located in the San Francisco Bay Area that is building novel diagnostics for acute infections and sepsis based on our unique immune biomarkers. Approximately $10 billion / year is spent trying to diagnose acute infections, but current technologies that focus on `finding the bug` are (1) slow and (2) effective in fewer than 30% of cases. Inflammatix has developed a statistically rigorous, extensively validated diagnostic method that `reads` the immune system. Our HostDx™ tests report clinically actionable information on the presence, type (bacterial or viral), and severity of infection in all patients. They have been extensively validated and published in top-tier medical journals. After this initial product, Inflammatix plans to develop and commercialize additional novel diagnostic tests to address significant unmet clinical needs.
Xilio is a Waltham, Massachusetts-based biopharmaceutical company focused on defeating cancer. The company`s proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body – a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. Xilio is applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer.
Precision BioSciences is a publicly held biotechnology company dedicated to improving life through its next generation gene editing technology, ARCUS. Precision`s cell therapy, gene therapy, and agriculture programs are based on the proprietary ARCUS gene editing platform, which features coordinated target site binding and DNA cutting to ensure precise edits. Our team includes pioneers in genome engineering, biotech business leaders, and a growing staff of committed Precisioneers. We work together in our beautifully designed, award-winning space in vibrant downtown Durham, NC; a place with great restaurants and museums as well as fantastic housing and schools. Precision provides all employees a sense of purpose, thoughtfully designed laboratory and office spaces, and opportunities to train and grow – not to mention plentifully stocked kitchens and fantastic benefits. At Precision BioSciences, we are excited to work together toward improving lives by realizing the potential of gene editing.